Benefits
Metabolic syndrome — multiple markers improve together
In adults with metabolic syndrome, ellagic acid at 1,000 mg/day (500 mg twice daily) for 12 weeks produces meaningful improvements across multiple cardiometabolic markers: waist circumference drops about 2.5 cm, systolic blood pressure drops about 5 mmHg, fasting glucose improves, triglycerides come down, and insulin sensitivity improves measurably. Reasonable adjunct alongside lifestyle changes; not a substitute for diet, exercise, or pharmaceutical therapy where indicated.
Type 2 diabetes — works alongside metformin
Adding ellagic acid to metformin produces better glycemic control than metformin alone over 8 weeks: lower fasting glucose, lower HbA1c, improved insulin sensitivity. Inflammatory markers (TNF-α, IL-6) and oxidative stress markers also improve. Useful as a complementary adjunct to standard diabetes care — the data specifically supports adding to metformin, not replacing it. Most relevant for patients whose HbA1c isn't quite at goal on metformin alone.
PCOS — insulin sensitivity and androgen reduction
In women with polycystic ovary syndrome, ellagic acid at 200 mg/day for 8 weeks reduces fasting insulin, improves HOMA-IR (insulin resistance score), and lowers total testosterone and free androgen index. Useful adjunct for the metabolic and hyperandrogenic components of PCOS — the two clusters of symptoms most resistant to lifestyle intervention alone. Reasonable consideration alongside standard PCOS care; not a replacement for inositol, metformin, or hormonal management where indicated.
Lipid profile improvement
Pooled across multiple trials, ellagic acid produces modest but reproducible improvements in lipid markers: lower triglycerides, lower total cholesterol, and lower LDL. Effect sizes are small compared to statins but meaningful as part of a broader strategy. Most relevant in metabolic syndrome and prediabetes contexts where multiple cardiometabolic markers need attention simultaneously, rather than as a standalone lipid intervention.
Mechanism of action
Urolithin conversion (gut microbial bioactivation)
Ellagic acid itself has very low bioavailability (~1%). Gut bacteria — particularly Gordonibacter species — convert ellagic acid (and ellagitannins like punicalagin) into urolithin A, urolithin B, and isourolithin A through stepwise dehydroxylation. Urolithins are absorbed and reach plasma concentrations of 0.2-20 μM. Individuals show three urolithin metabotypes (A, B, 0) based on microbiome composition — explaining why some respond and others don't.
AMPK activation and GLUT-4 translocation
Ellagic acid activates AMP-activated protein kinase and ERK signaling, increasing GLUT-4 translocation in skeletal muscle and adipose tissue. This explains the improvement in fasting glucose and insulin sensitivity observed across multiple human RCTs.
Resistin suppression and adipogenesis inhibition
Ellagic acid suppresses adipocyte secretion of resistin — an adipocytokine that drives insulin resistance. Concurrently, ellagic acid inhibits 3T3-L1 preadipocyte differentiation by interrupting Rb phosphorylation and the cell cycle. These mechanisms explain effects on abdominal obesity and metabolic parameters.
eNOS upregulation (blood pressure mechanism)
In a rat L-NAME hypertension model, ellagic acid restores endothelial nitric oxide synthase expression and reduces p47phox (NADPH oxidase). This produces blood pressure reduction in hypertensive — but not normotensive — animals, explaining the BP reductions observed in human metabolic syndrome trials.
Clinical trials
Randomized, double-blind, placebo-controlled clinical trial (Hidalgo-Lozada GM, Villarruel-López A, Martínez-Abundis E, Vázquez-Paulino O, González-Ortiz M, Pérez-Rubio KG 2022, J Clin Med 11(19):5741, doi:10.3390/jcm11195741).
32 adults aged 30-59 with metabolic syndrome diagnosis (International Diabetes Federation criteria). Randomized to ellagic acid (500 mg pomegranate extract, 90% EA) twice daily or placebo (calcined magnesia) for 12 weeks. 30 completed analysis (15 per arm).
Ellagic acid significantly improved all assessed metabolic syndrome components vs placebo: waist circumference (males -3.8 cm, females -2.7 cm, p<0.05), systolic BP (-4.9 mmHg, p=0.011), diastolic BP (-3.1 mmHg, p=0.013), fasting glucose (-0.8 mmol/L, p=0.001), triglycerides (-0.7 mmol/L, p=0.001), insulin sensitivity (Matsuda index +1.4, p=0.001), insulin secretion (Stumvoll first-phase, p=0.011), and HDL-c in males (p=0.002). Body weight reduced 1.5 kg (p=0.001) and uric acid -20.6 µmol/L (p=0.002). No serious adverse events; AST/ALT/creatinine unchanged.
Randomized double-blind clinical trial (Ghadimi M, Foroughi F, Hashemipour S, Nooshabadi MR, Ahmadi MH, Nezhad BA, Haghighian HK 2021, Phytother Res 35(2):1023-1032, doi:10.1002/ptr.6867).
Patients with type 2 diabetes treated with metformin. Randomized to ellagic acid + metformin or placebo + metformin.
Ellagic acid supplementation significantly reduced fasting blood glucose, HbA1c, insulin levels, and HOMA-IR vs placebo. Antioxidant capacity increased (SOD, CAT, GPX) and inflammatory markers decreased (TNF-α, IL-6). Established complementary role to metformin in T2D management with improvements in both glycemic and inflammatory parameters.
Randomized double-blind clinical trial (Kazemi M, Lalooha F, Nooshabadi MR, Dashti F, Kavianpour M, Haghighian HK 2021, J Ovarian Res 14(1):100, doi:10.1186/s13048-021-00849-2).
Women with polycystic ovary syndrome (PCOS) randomized to ellagic acid 200 mg/day or placebo for 8 weeks.
Ellagic acid significantly reduced fasting insulin, HOMA-IR, total testosterone, free androgen index, malondialdehyde (oxidative stress) vs placebo. Total antioxidant capacity, SOD, and GPX activity increased. Established a role for ellagic acid in addressing both metabolic (insulin resistance) and androgenic components of PCOS.